Literature DB >> 31150736

Establishing Pure Cancer Organoid Cultures: Identification, Selection and Verification of Cancer Phenotypes and Genotypes.

Nina Wallaschek1, Carolin Niklas1, Malvika Pompaiah2, Armin Wiegering3, Christoph-Thomas Germer3, Stefan Kircher4, Stephanie Brändlein4, Katja Maurus4, Andreas Rosenwald4, Helen H N Yan5, Suet Y Leung6, Sina Bartfeld7.   

Abstract

Precision medicine requires in vitro models which will both faithfully recapitulate the features of an individual's disease and enable drug testing on a wide variety of samples covering the greatest range of phenotypes possible for a particular disease. Organoid technology has immense potential to fulfill this demand, but it will be necessary to develop robust protocols that enable the generation of organoids in a dependable manner from nearly every patient. Here we provide a user's guide, including detailed step-by-step protocols, to the establishment, isolation and verification of gastric cancer organoids. Selection strategies include omission of growth factors, addition of drugs, isolation of distinct phenotypes and generation of monoclonal lines. For confirmation of cancer identity, we use sequencing, drug selection, karyotyping and histology. While we specify these protocols for human gastric cancer organoids here, the methods described are applicable to organoids derived from other tissues as well.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  cancer organoids; disease models; selection strategies; stomach

Mesh:

Substances:

Year:  2019        PMID: 31150736     DOI: 10.1016/j.jmb.2019.05.031

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  7 in total

1.  ERK3/MAPK6 controls IL-8 production and chemotaxis.

Authors:  Katarzyna Bogucka; Malvika Pompaiah; Federico Marini; Harald Binder; Gregory Harms; Manuel Kaulich; Matthias Klein; Christian Michel; Markus P Radsak; Sebastian Rosigkeit; Peter Grimminger; Hansjörg Schild; Krishnaraj Rajalingam
Journal:  Elife       Date:  2020-04-21       Impact factor: 8.140

2.  Establishment of Patient-Derived Gastric Cancer Organoid Model From Tissue Obtained by Endoscopic Biopsies.

Authors:  Hana Song; Jae Yong Park; Ju-Hee Kim; Tae-Seop Shin; Soon Auck Hong; Md Nazmul Huda; Beom Jin Kim; Jae Gyu Kim
Journal:  J Korean Med Sci       Date:  2022-07-18       Impact factor: 5.354

Review 3.  Patient-Derived Cancer Organoids as Predictors of Treatment Response.

Authors:  Maikel Verduin; Ann Hoeben; Dirk De Ruysscher; Marc Vooijs
Journal:  Front Oncol       Date:  2021-03-18       Impact factor: 6.244

4.  Ephrin receptor A2, the epithelial receptor for Epstein-Barr virus entry, is not available for efficient infection in human gastric organoids.

Authors:  Nina Wallaschek; Saskia Reuter; Sabrina Silkenat; Katharina Wolf; Carolin Niklas; Özge Kayisoglu; Carmen Aguilar; Armin Wiegering; Christoph-Thomas Germer; Stefan Kircher; Andreas Rosenwald; Claire Shannon-Lowe; Sina Bartfeld
Journal:  PLoS Pathog       Date:  2021-02-17       Impact factor: 6.823

Review 5.  Urological cancer organoids, patients' avatars for precision medicine: past, present and future.

Authors:  Haotian Chen; Wentao Zhang; Niraj Maskey; Fuhan Yang; Zongtai Zheng; Cheng Li; Ruiliang Wang; Pengfei Wu; Shiyu Mao; Junfeng Zhang; Yang Yan; Wei Li; Xudong Yao
Journal:  Cell Biosci       Date:  2022-08-19       Impact factor: 9.584

Review 6.  Organoid models of gastrointestinal cancers in basic and translational research.

Authors:  Harry Cheuk Hay Lau; Onno Kranenburg; Haipeng Xiao; Jun Yu
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-02-25       Impact factor: 46.802

Review 7.  Gastric organoids-an in vitro model system for the study of gastric development and road to personalized medicine.

Authors:  Therese Seidlitz; Bon-Kyoung Koo; Daniel E Stange
Journal:  Cell Death Differ       Date:  2020-11-22       Impact factor: 15.828

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.